Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

The Prostate Pub Date : 2024-04-29 DOI:10.1002/pros.24721
Andrea K. Miyahira, Sophia C. Kamran, Tamara Jamaspishvili, Catherine H. Marshall, Kara N. Maxwell, Abhijit Parolia, Nicholas A. Zorko, Kenneth J. Pienta, Howard R. Soule
{"title":"Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting","authors":"Andrea K. Miyahira, Sophia C. Kamran, Tamara Jamaspishvili, Catherine H. Marshall, Kara N. Maxwell, Abhijit Parolia, Nicholas A. Zorko, Kenneth J. Pienta, Howard R. Soule","doi":"10.1002/pros.24721","DOIUrl":null,"url":null,"abstract":"IntroductionThe 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023.MethodsThe 2023 marked the 10th Annual CHPCA Meeting, a discussion‐oriented scientific think‐tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions.ResultsThe central topic areas covered at the meeting included: targeting transcription factor neo‐enhancesomes in cancer, AR as a pro‐differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence‐driven precision medicine.DiscussionThis article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prostate","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pros.24721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

IntroductionThe 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023.MethodsThe 2023 marked the 10th Annual CHPCA Meeting, a discussion‐oriented scientific think‐tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions.ResultsThe central topic areas covered at the meeting included: targeting transcription factor neo‐enhancesomes in cancer, AR as a pro‐differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence‐driven precision medicine.DiscussionThis article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
颠覆前列腺癌研究:接受挑战;2023 年科菲-霍尔登前列腺癌研究院会议报告
导言2023年科菲-霍登前列腺癌学会(CHPCA)会议于6月22日至25日在加利福尼亚大学洛杉矶分校卢斯金会议中心召开,会议主题为 "颠覆前列腺癌研究,接受挑战":方法2023年是第10届CHPCA年会,这是一个以讨论为导向的科学智囊团会议,由前列腺癌基金会每年召开一次,主要讨论创新和新兴研究课题,这些课题被认为对推动前列腺癌研究和临床治疗中尚未满足的关键需求至关重要。2023 CHPCA 会议有 81 位学术研究人员参加,包括 8 个分会场的 40 场会谈。结果会议涉及的中心议题领域包括:靶向癌症中的转录因子新增强体、AR作为一种促进分化和致癌的转录因子、为什么雄激素剥夺疗法很少有人能治愈以及如何改变教条以治愈转移性前列腺癌而无需阉割、通过遗传学降低前列腺癌的发病率和死亡率、辐射增强寡转移性前列腺癌治疗效果的机会、新型免疫治疗方法以及人工智能驱动的精准医疗新时代。讨论本文概述了在2023年中国前列腺癌学术大会上发表的科学演讲,这些知识有助于推动全球前列腺癌研究的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones. Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer Responses to queries concerning "Performance of large language models on benign prostatic hyperplasia frequently asked questions".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1